The GRPR-targeted agents for both imaging and therapy achieved excellent tumor uptake, such as 111In-JMV4168 for luminal-subtype imaging (Dalm et al., 2015), 68Ga-NOTA-PEG3-RM26 for HER2-subtype imaging (Varasteh et al., 2014), 99mTc-BN4 for TNBC imaging (De et al., 2019), 177Lu-DOTA-DN(PTX)-BN for luminal-subtype therapy (Gibbens-Bandala et al., 2019a), and 177Lu-BN-PLGA (PTX) for TNBC therapy (Gibbens-Bandala et al., 2019b). The gene discussed is ERBB2; the disease is neoplasm.